ARCHIVES

Secondary AML In High-Dose Chemo Trial Cause For Careful Monitoring, NCI Says

This article is from The Cancer Letter archive.

Vol. 20 No. 33 | August 19, 1994

Download PDF Visit The Full Archive

Related Articles

Michael Friedman To Head PhRMA’s Office Of Biomedical Preparedness.

November 2, 2001

NIH Reauthorization Still Lingering, Bills ‘Tie Hands’ Of NCI Director

October 18, 1991

FDA Throws Up IND Roadblock, Then Refuses To Answer Investigator’s Letters About It

February 6, 1976

“Optimal Criteria,” For Hospitals Treating Cancer Patients Developed; NCI Won’t Try Forcing Changes

November 1, 1974

In Brief: MSK Opens Laurence Rockefeller Pavilion; Bush Event raised 410 Million for Anderson

July 9, 1999

California To Help Uninsured Get Prostate Cancer Therapy.

July 13, 2001